Company Encyclopedia
View More
name
Sito Bio
300583.SZ
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a methyl epoxide, and hexahydro-3a-methyl, as well as androsta-1,4-diene-3,17-dione and estra-4,9-diene-3,17-dione. The company was founded in 2002 and is based in Heze City, China.
3.159 T
300583.SZMarket value -Rank by Market Cap -/-

Financial Score

06/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking213/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-9.31%D
    • Profit Margin-18.09%D
    • Gross Margin23.44%D
  • Growth ScoreE
    • Revenue YoY-14.87%E
    • Net Profit YoY-20505.88%E
    • Total Assets YoY-7.16%D
    • Net Assets YoY-9.88%D
  • Cash ScoreE
    • Cash Flow Margin-552.80%E
    • OCF YoY-14.87%E
  • Operating ScoreD
    • Turnover0.32D
  • Debt ScoreB
    • Gearing Ratio37.15%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sito Bio: The listing application for the chemical raw material drug Methylprednisolone has been approved

    Sito Bio's holding subsidiary, Shandong Sray Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration for the marketing application of methylprednisolone chemical raw materials. Methylprednisolone is a medium-acting, halogen-free corticosteroid medication suitable for emergency treatment and management of various diseases, including endocrine disorders, rheumatic diseases, and skin diseases

    Zhitong·
    SZ
    300583
    +0.81%
    Zhitong·
    SZ
    300583
    +0.81%

    Sito Bio released its performance for the first three quarters, with a net loss attributable to the parent company of 69.2303 million yuan

    According to the Zhitong Finance APP, Sito Bio released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 749 million yuan, a year-on-year decrease of 2.07%. The net loss attributable to shareholders of the listed company was 69.2303 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 72.3879 million yuan. The basic loss per share was 0.36 yuan

    Zhitong·
    SZ
    300583
    +0.81%
    Zhitong·
    SZ
    300583
    +0.81%

    Sito Bio: Subsidiary Srey Pharmaceuticals received the CEP certificate for Dexamethasone Sodium Phosphate raw materials

    Sito Bio announced that its holding subsidiary, Sray Pharmaceutical, recently received the European Pharmacopoeia suitability certificate for Dexamethasone Sodium Phosphate issued by the European Medicines Agency. The certificate is valid for five years starting from October 1, 2025. Dexamethasone Sodium Phosphate is a corticosteroid primarily used for allergic and autoimmune inflammatory diseases. According to IQVIA data, the global demand for Dexamethasone Sodium Phosphate raw materials is nearly 10 tons in 2024

    Zhitong·
    SZ
    300583
    +0.81%
    Zhitong·
    SZ
    300583
    +0.81%

    Sito Bio released its performance for the first half of the year, turning from profit to a loss of 52.6871 million yuan

    According to the Zhitong Finance APP, Sito Bio released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 508 million yuan, a year-on-year decrease of 10.39%. The net loss attributable to shareholders of the listed company was 52.6871 million yuan. The net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 53.4816 million yuan. The basic loss per share was 0.28 yuan

    Zhitong·
    SZ
    300583
    +0.81%
    Zhitong·
    SZ
    300583
    +0.81%

    Decrypting the stocks with major capital outflow: 587 stocks with a net outflow for 5 consecutive days

    As of July 18, there were a total of 587 stocks in the Shanghai and Shenzhen markets with main funds experiencing net outflows for 5 consecutive days or more. Sito Bio had the longest duration of net outflows, reaching 21 days; SERES had the largest net outflow amount, totaling 4.144 billion yuan. WFDSJ had the highest proportion of net outflows relative to trading volume, with a decline of 7.77% in the past 6 days

    Zhitong·
    SH
    601010
    -0.66%
    SZ
    300583
    +0.81%
    SH
    601127
    +0.10%
    Zhitong·
    SH
    601010
    -0.66%
    SZ
    300583
    +0.81%
    SH
    601127
    +0.10%
    © 2025 Longbridge｜Disclaimer